New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 29, 2010
11:16 EDTLLY, BCSI, WDC, CSTR, MNKD, DELLOn The Fly: Rumor Buzz
Market speculation today includes takeover chatter involving Coinstar (CSTR)...Blue Coat Systems (BCSI) advances about 4.9% and is again the subject of an unconfirmed takeover rumor. Dell (DELL) has previously been mentioned as a possible suitor...Western Digital Corp. (WDC) is up almost 3.5% on renewed takeover speculation...Unconfirmed is a rumor that Eli Lilly & Co. (LLY) is readying a $12.50 bid for MannKind Corp. (MNKD), up 2.9%.
News For CSTR;BCSI;DELL;WDC;LLY;MNKD From The Last 14 Days
Check below for free stories on CSTR;BCSI;DELL;WDC;LLY;MNKD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 22, 2014
05:10 EDTLLYEli Lilly announces FDA approval of Cyramza
Eli Lilly announced that the FDA has approved Cyramza as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction, or GEJ, adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. With this approval, CYRAMZA becomes the first FDA-approved treatment for patients in this setting.
April 21, 2014
16:16 EDTLLYEli Lilly's Cyramza gets FDA approval
Subscribe for More Information
06:14 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 17, 2014
03:54 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Stocks with implied volatility below IV index mean; Questcor (QCOR) 47, MannKind (MNKD) 82 according to iVolatility.
April 16, 2014
06:23 EDTMNKD Stocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 15, 2014
06:32 EDTLLYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
06:04 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 14, 2014
10:02 EDTLLYOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
09:04 EDTLLYEli Lilly and Boehringer Ingelheim's NDA accepted by FDA
Subscribe for More Information
05:57 EDTLLYEli Lilly upgraded to Hold from Underperform at Jefferies
Subscribe for More Information
05:54 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Stocks with implied volatility below IV index mean; Questcor (QCOR) 44, MannKind (MNKD) 83 according to iVolatility.
April 11, 2014
10:46 EDTMNKDOptions with decreasing implied volatility: MNKD QCOR NQ WWE BBBY
06:04 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 10, 2014
12:29 EDTMNKDMannKind retreats after potential rival starts IPO process
Shares of drug maker MannKind (MNKD) are falling after a potential competitor, Dance Biopharm, sought to launch an initial public offering. WHAT'S NEW: Dance Biopharm filed papers with the SEC to raise $75M through an IPO last night. Like Mannkind, Dance has developed an inhaled insulin product that is supposed to treat diabetes. Dance's lead product, Dance 501, is designed to deliver liquid insulin through a small, handheld electronic inhaler, Dance stated in its IPO application. The company plans to launch a Phase III trial of the product in early 2015 and eventually seek regulatory approval of the product in the EU, U.S., and China. MannKind's AFREZZA, which is designed to deliver insulin through an inhaler, is currently under review for approval by the FDA. PRICE ACTION: In early afternoon trading, MannKind sank 30c, or 4.3%, to $6.70.
11:03 EDTMNKDOptions with decreasing implied volatility: MNKD QCOR MU KMX
April 9, 2014
16:00 EDTMNKDOptions Update; April 9, 2014
Subscribe for More Information
15:41 EDTMNKDMannKind volatility decreases to 90
Subscribe for More Information
10:23 EDTMNKDOptions with decreasing implied volatility: MNKD QCOR MU KMX
Subscribe for More Information
08:03 EDTLLYEli Lilly and T1D to partner in diabetes research collaboration
Subscribe for More Information
05:56 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Stocks with implied volatility below IV index mean; Questcor (QCOR) 47, MannKind (MNKD) 83 according to iVolatility.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use